Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92-Reference-Cited by-同舟云学术

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Published:2018-09-06 Issue:10 Volume:132 Page:1050-1063
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Morelli Eugenio¹²,Biamonte Lavinia¹,Federico Cinzia¹³,Amodio Nicola¹,Di Martino Maria Teresa¹,Gallo Cantafio Maria Eugenia¹,Manzoni Martina⁴⁵^ORCID,Scionti Francesca¹,Samur Mehmet Kemal²,Gullà Annamaria¹²,Stamato Maria Angelica¹,Pitari Maria Rita¹,Caracciolo Daniele¹,Sesti Settimio⁶,Frandsen Niels M.⁷,Rossi Marco¹,Neri Antonino⁴⁵,Fulciniti Mariateresa²,Munshi Nikhil C.²⁸,Tagliaferri Pierosandro¹,Tassone Pierfrancesco¹

Affiliation:

1. Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy;

2. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

3. Cancer Biology Division, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO;

4. Department of Oncology and Oncoematology, University of Milan, Milan, Italy;

5. UOC Ematologia, Fondazione Cà Granda IRCCS, Ospedale Maggiore Policlinico, Milan, Italy;

6. Department of Biology, Ecology and Earth Science, University of Calabria, Cosenza, Italy;

7. Exiqon A/S, Vedbaek, Denmark; and

8. VA Boston Healthcare System, Boston, MA

Abstract

Key Points First-in-class MIR17PTi enables 1-shot downregulation of miR-17-92 in vitro and in vivo, with favorable pharmacokinetic profile. MIR17PTi affects homeostatic MYC/miR-17-92 FFLs in MM cells, resulting in strong anti-MM activity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/10/1050/1406751/blood836601.pdf

Reference41 articles.

1. The microRNA-17-92 family of microRNA clusters in development and disease;Concepcion;Cancer J,2012

2. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease;Mogilyansky;Cell Death Differ,2013

3. A microRNA polycistron as a potential human oncogene;He;Nature,2005

4. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies;Chesi;Cancer Cell,2008

5. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification;Ott;Blood,2013

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Avenanthramide A potentiates Bim-mediated antineoplastic properties of 5-fluorouracil via targeting KDM4C/MIR17HG/GSK-3β negative feedback loop in colorectal cancer;Acta Pharmaceutica Sinica B;2024-07

2. Beneficial Effect of Olive Oil and Its Derivates: Focus on Hematological Neoplasm;Life;2024-04-30

3. Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation;Current Research in Pharmacology and Drug Discovery;2024

4. Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption;British Journal of Cancer;2023-10-03

5. miR-92a-3p regulates cisplatin-induced cancer cell death;Cell Death & Disease;2023-09-13